Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer

Modern Pathology

Volumn 27, Issue 3, 2014, Pages 443-453

  Kim, Jung Ho ^a,b   Kim, Kyung Ju ^a   Rhee, Ye Young ^a   Oh, Sohee ^b   Cho, Nam Yun ^a   Lee, Hye Seung ^c   Kang, Gyeong Hoon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Chemotherapy; Colorectal cancer; HSP110; Microsatellite instability; Prognosis

Indexed keywords

FLUOROURACIL; HEAT SHOCK PROTEIN 110;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; FEMALE; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUES;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DELETION; HSP110 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84896722429     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.160     Document Type: Article

References (42)

1. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58: 90-96.
2. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133: 48-56.
3. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 2010;28: 3380-3387.
4. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23: 609-618.
5. Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010;46: 2788-2798.
6. Bae JM, Kim MJ, Kim JH, et al. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch 2011;459: 55-63.
7. Kim JH, Shin SH, Kwon HJ, et al. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009;455: 485-494.
8. Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68: 8541-8546.
9. Dahlin AM, Palmqvist R, Henriksson ML, et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010;16: 1845-1855.
10. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-2087; e2073.
11. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349: 247-257.
12. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite- unstable colorectal cancer. Gastroenterology 2004;126: 394-401.
13. Benatti P, Gafa R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11: 8332-8340.
14. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009;45: 1890-1896.
15. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28: 3219-3226.
16. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60: 116-129.
17. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21: 2396-2402.
18. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65: 6063-6069.
19. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28: 466-474.
20. Kloor M, Michel S, Buckowitz B, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007;121: 454-458.
21. Tikidzhieva A, Benner A, Michel S, et al. Microsatellite instability and Beta2-microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br J Cancer 106:1239-1245 2012.
22. Mazzolini R, Dopeso H, Mateo-Lozano S, et al. Brush border myosin Ia has tumor suppressor activity in the intestine. Proc Natl Acad Sci USA 2012;109: 1530-1535.
23. Isaksson-Mettavainio M, Palmqvist R, Dahlin AM, et al. High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis. Int J Cancer 2012;131: 779-788.
24. Rhee YY, Kim MJ, Bae JM, et al. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. Ann Surg Oncol 2012;19: 3441-3448.
25. Dorard C, de Thonel A, Collura A, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med 2011;17: 1283-1289.
26. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58: 5248-5257.
27. Bosman FT. World Health Organization., International Agency for Research on Cancer WHO Classification of Tumours of the Digestive System, 4th edn. International Agency for Research on Cancer: Lyon, 2010.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-174.
29. Seigneuric R, Mjahed H, Gobbo J, et al. Heat shock proteins as danger signals for cancer detection. Front Oncol 2011;1:37.
30. Goldstein MG, Li Z. Heat-shock proteins in infectionmediated inflammation-induced tumorigenesis. J Hematol Oncol 2009;2:5.
31. Madrigal-Matute J, Martin-Ventura JL, Blanco-Colio LM, et al. Heat-shock proteins in cardiovascular disease. Adv Clin Chem 2011;54: 1-43.
32. Adachi H, Katsuno M, Waza M, et al. Heat shock proteins in neurodegenerative diseases: pathogenic roles and therapeutic implications. Int J Hyperthermia 2009;25: 647-654.
33. Jego G, Hazoume A, Seigneuric R, et al. Targeting heat shock proteins in cancer. Cancer Lett 332:275-285 2013.
34. Calderwood SK, Ciocca DR. Heat shock proteins: stress proteins with Janus-like properties in cancer. Int J Hyperthermia 2008;24: 31-39.
35. Kampinga HH, Hageman J, Vos MJ, et al. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009;14: 105-111.
36. Slaby O, Sobkova K, Svoboda M, et al. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep 2009;21: 1235-1241.
37. Hwang TS, Han HS, Choi HK, et al. Differential, stagedependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol 2003;18: 690-700.
38. Van Rijnsoever M, Elsaleh H, Joseph D, et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9: 2898-2903.
39. Min BH, Bae JM, Lee EJ, et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011;11:344.
40. Jover R, Nguyen TP, Perez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011;140: 1174-1181.
41. Shen L, Catalano PJ, Benson AB 3rd, et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13: 6093-6098.
42. Han SW, Lee HJ, Bae JM, et al. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 2013;132: 2209-2216.